P454
The cannabinoid receptor type two is a therapeutic target for muscular dystrophy cardiomyopathy

Cardiovascular Research

23 April 2018

Organised by:

Read full article

Contributors

A Gowran

A Gowran

Author

E Castiglioni

E Castiglioni

Author

D Rovina

D Rovina

Author

F Casalnuovo

F Casalnuovo

Author

P Nigro

P Nigro

Author

P Spinelli

P Spinelli

Author

R Visone

R Visone

Author

M Rasponi

M Rasponi

Author

A Redaelli

A Redaelli

Author

G Pompilio

G Pompilio

Author

You may be interested in

Congress Presentation

The impact of the endocannabinoid system on the profibrotic profile of cardiac fibroblasts associated with DMD

14 May 2024

Congress Presentation

Therapeutic role of Prostaglandin E2 receptor 4 stimulation in inflammatory cardiomyopathy

30 August 2021

Congress Presentation

Cardiovascular magnetic resonance in neuromuscular disorders: looking ahead

10 May 2023

Congress Presentation

A phase 2a trial investigating ninerafaxstat - a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE)

26 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources